Canopy Growth Corporation has entered into an agreement to divest its subsidiary business, C3 Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE, a European pharmaceutical company headquartered in Grünwald, Germany. The C3 business develops and manufactures pharmaceutical products and is comprised of Spectrum Therapeutics GmbH, based in Neumarkt-in-der-Oberpfalz, Germany, THC Pharm GmbH The Health Concept, based in Frankfurt, Germany, and Spectrum Therapeutics Austria GmbH, based in Vienna, Austria. With the divesture of C3, Canopy Growth is continuing its evolution into a CPG-modelled organization and furthering its strategy of driving focus and consistent business across its core markets. The Company will continue to leverage its high-quality supply of Canadian cannabis products for the medical channel in its core international markets, including Germany, while also serving adult-use consumers in Canada.

Published Ncv Newswire, New Cannabis Ventures, 12/15/2021 08:50:00

Open article: